Applied BioCode Valuation Multiples

Applied BioCode Overview

About Applied BioCode

Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.

Founded

2016

HQ

Employees

N/A

Website

apbiocode.com

Sectors

Diagnostics & GenomicsMedical DevicesBioTechDeepTechLongevity

Financials (FY)

Revenue: $15M

EBITDA: ($4M)

EV

$60M

Valuation Multiples

Multiples.vc

Start free trial

Applied BioCode Financials

Applied BioCode reported last fiscal year revenue of $15M and negative EBITDA of ($4M).

In the same fiscal year, Applied BioCode generated $8M in gross profit, ($4M) in EBITDA losses, and had net loss of ($6M).

Applied BioCode P&L

In the most recent fiscal year, Applied BioCode reported revenue of $15M and EBITDA of ($4M).

Applied BioCode expects next 12-month revenue of XXX and NTM EBITDA of XXX

Applied BioCode Stock Performance

Applied BioCode has current market cap of $77M, and enterprise value of $60M.

Applied BioCode's stock price is $0.75.

Applied BioCode Valuation Multiples

Applied BioCode trades at 4.0x EV/Revenue multiple, and (13.4x) EV/EBITDA.

Applied BioCode Financial Valuation Multiples

As of March 28, 2026, Applied BioCode has market cap of $77M and EV of $60M.

Equity research analysts estimate Applied BioCode's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Applied BioCode has a P/E ratio of (12.3x).

Applied BioCode Margins & Growth Rates

Applied BioCode's revenue in the last fiscal year grew by 39%.

Applied BioCode Public Comps

See public comps and valuation multiples for other Diagnostics & Genomics and Medical Devices comps.

Applied BioCode M&A Activity

Applied BioCode acquired XXX companies to date.

Last acquisition by Applied BioCode was on XXXXXXXX, XXXXX. Applied BioCode acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Applied BioCode Investment Activity

Applied BioCode invested in XXX companies to date.

Applied BioCode made its latest investment on XXXXXXXX, XXXXX. Applied BioCode invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).